" class="no-js "lang="en-US"> John Reid - Medtech Alert
Sunday, April 14, 2024
John Reid

John Reid

About John Reid

Results oriented Patient Access Program Leader with 15+ years developing and implementing Patient Program excellence, improvement, and growth strategies. Expertise in combining senior leadership and development with process & financial metrics insights. Cross-function/Cross-department communication strengths within a matrix environment. Strong ability to set expectations, deliver implications and direction through data and clear, simple communications. Extensive experience launching and leading successful programs, partnering with internal and external vendor teams, maximizing profitability. Patient First mentality, strong partner with HCPs, Payers, Pharmacies.

Patient Services Hub Leader. Served as the business owner to stand up new benefit investigation, reimbursement, copay programs across multiple product launches, 2 high performing companies, 5 disease indications. Reaching and exceeding program goals for conversion rate, cycle time, quality, and REMS compliance.

Highly Effective Negotiator. Developed new business segments in Channel Operations including contract element development, partnership with legal and compliance, and relationship building with the client. Established a new Criminal Justice Pharmacy business and expanding a limited distribution product into Regional Territories, exceeding Regional targets by 400% in month one.

Data-driven Decision Maker. Coached and guided the C-Suite and Senior Department Leaders on Operational issues defining the Patient Journey and creating alternative paths to success while tempering expectations and bringing a calm confidence to the Launch Team. Optimized staff size, controlled operating expenses, exceeded Operational goals.

Strategic Advisor. Recommended and defended a robust Patient Services project/program list by partnering with Sales, Marketing, Finance, HR, Compliance. Key Advisor to the Vice President establishing trust and confidence across the portfolio. Balanced >$60 million Annual Operating Plan year over year including FTE Allowances and Operating Expenses.

Related Story

Cycle Pharmaceuticals Launches Cycle Vita ™, a Dedicated Support Platform for Rare Disease Patients

September 15 2021

Cycle Pharmaceuticals (Cycle) is pleased to announce the launch of its Boston-based support platform for […]